Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. Social Networks
  11. External Links
  12. Analytics And Tracking
  13. Libraries
  14. Hosting Providers
  15. CDN Services

We began analyzing https://www.nature.com/articles/nrc.2017.36, but it redirected us to https://www.nature.com/articles/nrc.2017.36. The analysis below is for the second page.

Title[redir]:
Drugging the 'undruggable' cancer targets | Nature Reviews Cancer
Description:
Nature Reviews Cancer - In this Viewpoint article, we asked four scientists working to target important, but so-called

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We see no obvious way the site makes money.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Doi.org might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

pubmed, cancer, google, scholar, cas, nature, central, myc, article, drug, targeting, access, cell, soucek, nat, targets, research, therapy, rev, content, undruggable, inhibitors, dang, kras, usa, cookies, drugging, laura, proteins, ras, resistance, therapeutic, biol, res, molecular, privacy, shokat, development, target, clin, discov, chem, data, information, reviews, chi, reddy, future, open, science,

Topics {✒️}

nature portfolio journals permissions reprints privacy policy nature portfolio advertising kras-g12c-targeting drugs licensed scientific founder social media european research council tki-treated lung adenocarcinoma small-cell lung cancer cancer research ras/mek/erk pathways prolongs rbc half-life her2-elf3-kras axis nature+ nature 503 nature 497 nature 468 nature 538 nature 514 nature 535 nature 455 nature small-molecule inhibitors personal data research viewpoint article data protection permissions androgen receptor inhibitors ras-transformed cells springerlink instant access targeted protein degradation ras superfamily gefs privacy targeting disordered proteins dragging ras back oncogene ews–fli1 oncogenic kras output subscription content small molecules targeting cancer genome landscapes diverse cancer models laura soucek oncogenic kras addiction explore content 'undruggable' cancer targets development institutional subscriptions read

Questions {❓}

  • Drugging the undruggable RAS: mission possible?
  • How to unleash mitochondrial apoptotic blockades to kill cancers?
  • Is NF-κB a good target for cancer therapy?
  • Nanoparticle-siRNA: a potential cancer therapy?
  • Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Drugging the 'undruggable' cancer targets
         description:In this Viewpoint article, we asked four scientists working to target important, but so-called 'undruggable', proteins in cancer for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of cancer research. The term 'undruggable' was coined to describe proteins that could not be targeted pharmacologically. However, progress is being made to 'drug' many of these targets, and therefore more appropriate terms might be 'difficult to drug' or 'yet to be drugged'. Many desirable targets in cancer fall into this category, including the RAS and MYC oncogenes, and pharmacologically targeting these intractable proteins is now a key challenge in cancer research that requires innovation and the development of new technologies. In this Viewpoint article, we asked four scientists working in this field for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of research.
         datePublished:2017-06-23T00:00:00Z
         dateModified:2017-06-23T00:00:00Z
         pageStart:502
         pageEnd:508
         sameAs:https://doi.org/10.1038/nrc.2017.36
         keywords:
            Drug development
            Oncogenes
            Targeted therapies
            Tumour-suppressor proteins
            Biomedicine
            general
            Cancer Research
         image:
         isPartOf:
            name:Nature Reviews Cancer
            issn:
               1474-1768
               1474-175X
            volumeNumber:17
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Chi V. Dang
               affiliation:
                     name:Abramson Cancer Center, University of Pennsylvania
                     address:
                        name:Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
                     name:Present addresses: Ludwig Institute for Cancer Research, New York, New York 10017, USA, and The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
                     address:
                        name:Present addresses: Ludwig Institute for Cancer Research, New York, New York 10017, USA, and The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.,
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:E. Premkumar Reddy
               affiliation:
                     name:Icahn School of Medicine at Mount Sinai
                     address:
                        name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Kevan M. Shokat
               affiliation:
                     name:University of California, San Francisco & Howard Hughes Medical Institute
                     address:
                        name:Department of Cellular and Molecular Pharmacology, University of California, San Francisco & Howard Hughes Medical Institute, San Francisco, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Laura Soucek
               affiliation:
                     name:Vall d'Hebron Institute of Oncology (VHIO)
                     address:
                        name:Vall d'Hebron Institute of Oncology (VHIO), Barcelona
                        type:PostalAddress
                     type:Organization
                     name:Vall d'Hebron Institute of Oncology (VHIO)
                     address:
                        name:Vall d'Hebron Institute of Oncology (VHIO), Barcelona
                        type:PostalAddress
                     type:Organization
                     name:Institució Catalana de Recerca i Estudis Avançats (ICREA)
                     address:
                        name:Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona
                        type:PostalAddress
                     type:Organization
                     name:Universitat Autònoma de Barcelona
                     address:
                        name:Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Drugging the 'undruggable' cancer targets
      description:In this Viewpoint article, we asked four scientists working to target important, but so-called 'undruggable', proteins in cancer for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of cancer research. The term 'undruggable' was coined to describe proteins that could not be targeted pharmacologically. However, progress is being made to 'drug' many of these targets, and therefore more appropriate terms might be 'difficult to drug' or 'yet to be drugged'. Many desirable targets in cancer fall into this category, including the RAS and MYC oncogenes, and pharmacologically targeting these intractable proteins is now a key challenge in cancer research that requires innovation and the development of new technologies. In this Viewpoint article, we asked four scientists working in this field for their opinions on the most crucial advances, as well as the challenges and what the future holds for this important area of research.
      datePublished:2017-06-23T00:00:00Z
      dateModified:2017-06-23T00:00:00Z
      pageStart:502
      pageEnd:508
      sameAs:https://doi.org/10.1038/nrc.2017.36
      keywords:
         Drug development
         Oncogenes
         Targeted therapies
         Tumour-suppressor proteins
         Biomedicine
         general
         Cancer Research
      image:
      isPartOf:
         name:Nature Reviews Cancer
         issn:
            1474-1768
            1474-175X
         volumeNumber:17
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Chi V. Dang
            affiliation:
                  name:Abramson Cancer Center, University of Pennsylvania
                  address:
                     name:Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
                  name:Present addresses: Ludwig Institute for Cancer Research, New York, New York 10017, USA, and The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
                  address:
                     name:Present addresses: Ludwig Institute for Cancer Research, New York, New York 10017, USA, and The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.,
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:E. Premkumar Reddy
            affiliation:
                  name:Icahn School of Medicine at Mount Sinai
                  address:
                     name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Kevan M. Shokat
            affiliation:
                  name:University of California, San Francisco & Howard Hughes Medical Institute
                  address:
                     name:Department of Cellular and Molecular Pharmacology, University of California, San Francisco & Howard Hughes Medical Institute, San Francisco, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Laura Soucek
            affiliation:
                  name:Vall d'Hebron Institute of Oncology (VHIO)
                  address:
                     name:Vall d'Hebron Institute of Oncology (VHIO), Barcelona
                     type:PostalAddress
                  type:Organization
                  name:Vall d'Hebron Institute of Oncology (VHIO)
                  address:
                     name:Vall d'Hebron Institute of Oncology (VHIO), Barcelona
                     type:PostalAddress
                  type:Organization
                  name:Institució Catalana de Recerca i Estudis Avançats (ICREA)
                  address:
                     name:Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona
                     type:PostalAddress
                  type:Organization
                  name:Universitat Autònoma de Barcelona
                  address:
                     name:Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Reviews Cancer
      issn:
         1474-1768
         1474-175X
      volumeNumber:17
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Abramson Cancer Center, University of Pennsylvania
      address:
         name:Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
         type:PostalAddress
      name:Present addresses: Ludwig Institute for Cancer Research, New York, New York 10017, USA, and The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
      address:
         name:Present addresses: Ludwig Institute for Cancer Research, New York, New York 10017, USA, and The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.,
         type:PostalAddress
      name:Icahn School of Medicine at Mount Sinai
      address:
         name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
         type:PostalAddress
      name:University of California, San Francisco & Howard Hughes Medical Institute
      address:
         name:Department of Cellular and Molecular Pharmacology, University of California, San Francisco & Howard Hughes Medical Institute, San Francisco, USA
         type:PostalAddress
      name:Vall d'Hebron Institute of Oncology (VHIO)
      address:
         name:Vall d'Hebron Institute of Oncology (VHIO), Barcelona
         type:PostalAddress
      name:Vall d'Hebron Institute of Oncology (VHIO)
      address:
         name:Vall d'Hebron Institute of Oncology (VHIO), Barcelona
         type:PostalAddress
      name:Institució Catalana de Recerca i Estudis Avançats (ICREA)
      address:
         name:Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona
         type:PostalAddress
      name:Universitat Autònoma de Barcelona
      address:
         name:Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Chi V. Dang
      affiliation:
            name:Abramson Cancer Center, University of Pennsylvania
            address:
               name:Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
               type:PostalAddress
            type:Organization
            name:Present addresses: Ludwig Institute for Cancer Research, New York, New York 10017, USA, and The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.
            address:
               name:Present addresses: Ludwig Institute for Cancer Research, New York, New York 10017, USA, and The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.,
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:E. Premkumar Reddy
      affiliation:
            name:Icahn School of Medicine at Mount Sinai
            address:
               name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Kevan M. Shokat
      affiliation:
            name:University of California, San Francisco & Howard Hughes Medical Institute
            address:
               name:Department of Cellular and Molecular Pharmacology, University of California, San Francisco & Howard Hughes Medical Institute, San Francisco, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Laura Soucek
      affiliation:
            name:Vall d'Hebron Institute of Oncology (VHIO)
            address:
               name:Vall d'Hebron Institute of Oncology (VHIO), Barcelona
               type:PostalAddress
            type:Organization
            name:Vall d'Hebron Institute of Oncology (VHIO)
            address:
               name:Vall d'Hebron Institute of Oncology (VHIO), Barcelona
               type:PostalAddress
            type:Organization
            name:Institució Catalana de Recerca i Estudis Avançats (ICREA)
            address:
               name:Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona
               type:PostalAddress
            type:Organization
            name:Universitat Autònoma de Barcelona
            address:
               name:Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
      name:Present addresses: Ludwig Institute for Cancer Research, New York, New York 10017, USA, and The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.,
      name:Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, USA
      name:Department of Cellular and Molecular Pharmacology, University of California, San Francisco & Howard Hughes Medical Institute, San Francisco, USA
      name:Vall d'Hebron Institute of Oncology (VHIO), Barcelona
      name:Vall d'Hebron Institute of Oncology (VHIO), Barcelona
      name:Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona
      name:Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Bellaterra, Spain
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(2)

External Links {🔗}(314)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Foundation
  • Particles.js
  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

4.19s.